arrow
B

Biagio De Angelis

bambino gesu childrens hospital
H指数:32
被引数:3,592

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression

替伊鲁单抗β联合TEMIRI化疗在复发/难治性神经母细胞瘤中的应用:关于GD2表达这一开放性问题的真实世界见解

2026-09-010
OAAI
The polymeric nanovectors landscape for cancer immunotherapies towards advanced therapy medicinal products (ATMPs)

用于癌症免疫治疗的聚合物纳米载体景观,面向先进治疗药物产品(ATMPs)

2026-07-160
OAAI
An in vivo CRISPR screen unveils promising target genes to improve CAR-T cell efficacy in a solid tumor model

体内CRISPR筛选揭示了在实体瘤模型中提高CAR-T细胞疗效的有前景的靶基因

2026-04-040
PRE
Anti-CD7 fratricide-resistant chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia

针对复发/难治性急性髓系白血病的抗CD7 fratricide耐受性嵌合抗原受体(CAR)T细胞

Blood
IF23.1
2026-03-050
PRE
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

Anti-CD19 CAR T细胞治疗难治性自身免疫性疾病的儿科患者

2026-02-050
PRE
Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3–FOXO1 rhabdomyosarcoma

Neddylation抑制诱导DNA双链断裂,阻碍体内肿瘤生长,并促进PAX3–FOXO1横纹肌肉瘤的放射敏感性。

2025-11-030
OAAI
Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case report

接受抗-GD2单克隆抗体dinutuximab beta治疗的儿童多发性转移性视网膜母细胞瘤患者获得长期总生存:病例报告

2025-10-170
OAAI
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial

GD2靶向CAR T细胞在高风险神经母细胞瘤中的应用:一项I/II期临床试验。Nat. Med

2025-08-210
PRE
Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse

用于儿科或年轻成人复发性/难治性或极高危首次复发的BCP-ALL的床旁新鲜CAR T细胞

2025-06-260
OAAI
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring

欧洲CAR T细胞分析方法的调查:从apheresis到输注后免疫监测

2025-04-240
OA
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells

肿瘤衍生的g-csf在骨肉瘤模型中诱导免疫抑制微环境,降低对CAR.GD2 T细胞的反应

2024-12-180
OAAI
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks
2024-08-062
OAAI
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting
2023-12-153
OAAI
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies
2023-06-0921
OAAI
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

复发或难治性高危神经母细胞瘤的GD2-CART01

2023-04-06200
PRE
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors

将car-t细胞带入大脑的特殊挑战: 临床应用于治疗小儿中枢神经系统肿瘤的观点

2023-03-218
OAAI
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia

基于CAR.CD123-NK细胞的安全有效的现成免疫疗法治疗急性髓系白血病

2022-11-0544
OAAI